Investor Presentation First Nine Months of 2023

Sales growth of 33% driven by both operating units Novo NordiskⓇ Reported geographic sales split for first nine months of 2023 Reported therapy area sales and growth for first nine months of 2023 DKK billion Insulin Obesity care GLP-1 Other diabetes Rare disease Growth at CER DKK billion North America Operations International Operations Growth at CER 180 33% 49% -7% 174% -18% 100 49% 5 Investor presentation First nine months of 2023 60 80 60 60 40 40 20 20 90 90 60 60 60% 16% IO -1% NAO -24% IO 52% NAO 244% 49% 12% 30 43% ΙΟ -22% NAO -13% 150 17% International Operations 120 17% 19% 0 0 NAO ΙΟ EMEA China ROW Total GLP-1 Insulin Obesity care Rare disease IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; ROW: Rest of World; NAO: North America Operations; CER: Constant exchange rates Note: Unless otherwise specified, sales growth rates are at CER 1'Other diabetes' is included in Total

View entire presentation